214 related articles for article (PubMed ID: 33389590)
1. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report.
Shimizu Y; Sunagozaka H; Yamagata K; Hirai H; Miura M; Yonemoto Y; Naito Y; Hasatani K; Yoshikawa J; Aoyagi H; Kaneko S
Clin J Gastroenterol; 2021 Apr; 14(2):645-649. PubMed ID: 33389590
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma.
Ishigaki K; Hamada T; Nakai Y; Ishigaki Y; Oyama H; Kanai S; Suzuki T; Nakamura T; Sato T; Hakuta R; Saito K; Saito T; Takahara N; Mizuno S; Kogure H; Tateishi R; Tada M; Koike K
Clin J Gastroenterol; 2020 Aug; 13(4):568-571. PubMed ID: 32242306
[TBL] [Abstract][Full Text] [Related]
3. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report.
Shiozawa K; Watanabe M; Takenaka H; Nagai H; Ishii K; Sakai K; Sumino Y
Hepatogastroenterology; 2010; 57(101):688-90. PubMed ID: 21033210
[TBL] [Abstract][Full Text] [Related]
4. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.
Kosaka Y; Kawaoka T; Aikata H; Suehiro Y; Yamaoka K; Ando Y; Namba M; Takeuchi Y; Fujii Y; Uchikawa S; Kodama K; Oya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Kimura T; Nagata Y; Chayama K
Clin J Gastroenterol; 2020 Oct; 13(5):839-843. PubMed ID: 31974811
[TBL] [Abstract][Full Text] [Related]
5. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.
Miyajima S; Tsuji K; Kito Y; Yoshida N; Matsunaga K; Tsuji S; Katayanagi K; Yonezawa M; Kubo A; Ushijima K; Minato H; Doyama H
Clin J Gastroenterol; 2021 Feb; 14(1):187-192. PubMed ID: 33025343
[TBL] [Abstract][Full Text] [Related]
6. Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma.
Suoh M; Fujii H; Nagata Y; Kotani K; Hagihara A; Enomoto M; Tamori A; Inaba M; Kawada N
Clin J Gastroenterol; 2020 Oct; 13(5):860-866. PubMed ID: 32128670
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
Namba M; Kawaoka T; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Chayama K
Clin J Gastroenterol; 2019 Aug; 12(4):341-346. PubMed ID: 30706429
[TBL] [Abstract][Full Text] [Related]
8. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report.
Liu Z; Li X; He X; Xu Y; Wang X
BMC Cancer; 2019 Nov; 19(1):1062. PubMed ID: 31703571
[TBL] [Abstract][Full Text] [Related]
9. [Tumor lysis syndrome after transarterial embolization for hepatocellular carcinoma].
Nishida Y; Fujii H; Hagihara A; Kawamura E; Iwai S; Enomoto M; Tamori A; Arakawa T; Kawada N
Nihon Shokakibyo Gakkai Zasshi; 2013 Mar; 110(3):441-8. PubMed ID: 23459539
[TBL] [Abstract][Full Text] [Related]
10. Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib.
Sato A; Imai Y; Uchiya H; Uchida Y; Nakazawa M; Sugawara K; Nakayama N; Mochida S
Intern Med; 2022 Aug; 61(15):2301-2305. PubMed ID: 35283380
[TBL] [Abstract][Full Text] [Related]
11. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.
Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Tanaka H; Hirai K; Sakamoto I; Ogawa T; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Feb; 15(1):177-184. PubMed ID: 34811701
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.
Imakura T; Sato S; Tomonari T; Murakami K; Takahashi N; Naito N; Mima M; Kagawa K; Koyama K; Nishimura H; Kawano H; Nokihara H; Azuma M; Takayama T; Nishioka Y
Intern Med; 2022 Apr; 61(8):1211-1217. PubMed ID: 34544944
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
14. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
[TBL] [Abstract][Full Text] [Related]
15. Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma.
Ishizaki M; Kaibori M; Matsushima H; Kosaka H; Matsui K; Sekimoto M
Clin J Gastroenterol; 2021 Dec; 14(6):1700-1705. PubMed ID: 34480729
[TBL] [Abstract][Full Text] [Related]
16. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
17. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
18. A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
Joshita S; Yoshizawa K; Sano K; Kobayashi S; Sekiguchi T; Morita S; Kamijo A; Komatsu M; Umemura T; Ichijo T; Matsumoto A; Tanaka E
Intern Med; 2010; 49(11):991-4. PubMed ID: 20519814
[TBL] [Abstract][Full Text] [Related]
19. A case of hepatocellular carcinoma with pseudoaneurysm formation upon lenvatinib administration.
Yano R; Hirooka M; Nakamura Y; Imai Y; Koizumi Y; Watanabe T; Yoshida O; Tokumoto Y; Abe M; Hiasa Y
Clin J Gastroenterol; 2024 Apr; 17(2):319-326. PubMed ID: 38281290
[TBL] [Abstract][Full Text] [Related]
20. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
